Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Daiichi Sankyo
US Army
Argus Health
Chubb
McKinsey
Dow
Fish and Richardson
Boehringer Ingelheim

Generated: February 24, 2018

DrugPatentWatch Database Preview

Selegiline - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for selegiline and what is the scope of selegiline patent protection?

Selegiline
is the generic ingredient in four branded drugs marketed by Somerset, Apotex, Dava Pharms Inc, Lannett Holdings Inc, Valeant Pharm Intl, Apotex Inc, Boscogen, Chartwell Molecules, G And W Labs Inc, Mylan, and Siegfried, and is included in sixteen NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Selegiline has three patent family members in two countries.

There are seventeen drug master file entries for selegiline. One supplier is listed for this compound.

US Patents and Regulatory Information for selegiline

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apotex Inc SELEGILINE HYDROCHLORIDE selegiline hydrochloride TABLET;ORAL 074871-001 Jun 6, 1997 AB RX No Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Somerset ELDEPRYL selegiline hydrochloride CAPSULE;ORAL 020647-001 May 15, 1996 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Somerset EMSAM selegiline FILM, EXTENDED RELEASE;TRANSDERMAL 021336-002 Feb 27, 2006 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
G And W Labs Inc SELEGILINE HYDROCHLORIDE selegiline hydrochloride TABLET;ORAL 074744-001 Jan 27, 1997 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Somerset EMSAM selegiline FILM, EXTENDED RELEASE;TRANSDERMAL 021336-003 Feb 27, 2006 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Somerset EMSAM selegiline FILM, EXTENDED RELEASE;TRANSDERMAL 021336-001 Feb 27, 2006 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Boscogen SELEGILINE HYDROCHLORIDE selegiline hydrochloride TABLET;ORAL 074912-001 Apr 30, 1998 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Somerset EMSAM selegiline FILM, EXTENDED RELEASE;TRANSDERMAL 021336-003 Feb 27, 2006 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Somerset EMSAM selegiline FILM, EXTENDED RELEASE;TRANSDERMAL 021336-003 Feb 27, 2006 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Mylan SELEGILINE HYDROCHLORIDE selegiline hydrochloride TABLET;ORAL 074866-001 Nov 26, 1997 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for selegiline

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Somerset EMSAM selegiline FILM, EXTENDED RELEASE;TRANSDERMAL 021336-001 Feb 27, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Somerset EMSAM selegiline FILM, EXTENDED RELEASE;TRANSDERMAL 021336-002 Feb 27, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Somerset EMSAM selegiline FILM, EXTENDED RELEASE;TRANSDERMAL 021336-003 Feb 27, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for selegiline

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,846,093 Adhesive mixture for transdermal delivery of highly plasticizing drugs ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Teva
Harvard Business School
QuintilesIMS
Johnson and Johnson
Deloitte
Covington
AstraZeneca
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot